DOCSLIB.ORG

HEDIS®1 Public Comment Overview

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HEDIS®1 Public Comment Overview HEDIS®1 Public Comment Overview HEDIS Overview HEDIS is a set of standardized performance measures designed to ensure that purchasers and consumers can reliably compare the performance of health plans. It also serves as a model for emerging systems of performance measurement in other areas of health care delivery. HEDIS is maintained by NCQA, a not-for-profit organization committed to evaluating and publicly reporting on the quality of health plans, ACOs, physicians, and other organizations. The HEDIS measurement set consists of 92 measures across 6 domains of care. Items available for public comment are being considered for HEDIS Measurement Year 2022, which will be published in August 2021. HEDIS Measure Development Process NCQA’s consensus development process involves rigorous review of published guidelines and scientific evidence, as well as feedback from multi-stakeholder advisory panels. The NCQA Committee on Performance Measurement, a diverse panel of independent scientists and representatives from health plans, consumers, federal policymakers, purchasers and clinicians, oversees the evolution of the HEDIS measurement set. Numerous measurement advisory panels provide clinical and technical knowledge required to develop the measures. Additional HEDIS expert panels and the Technical Measurement Advisory Panel provide invaluable assistance by identifying methodological issues and giving feedback on new and existing measures. Synopsis NCQA seeks public feedback on proposed new HEDIS measures, revisions to existing measures and proposed measure retirement. Reviewers are asked to submit comments to NCQA in writing via the Public Comment website by 11:59 p.m. (ET), Thursday, March 11. Submitting Comments Submit all comments via NCQA’s Public Comment website at https://my.ncqa.org/ Note: NCQA does not accept comments via mail, email or fax. 1HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). How to Submit a Comment 1. Go to https://my.ncqa.org/. 2. Once logged in, click to select Public Comment. 3. Click Add Comment. 4. In the Product field, click to select HEDIS Public Comment from the drop-down menu. 5. Click the Instructions link to view public comment materials, including instructions and proposed measure specifications. 6. Click to select the Topic and Element (measure) on which you want to comment. 7. Click to select your support option (e.g., Support, Do not support, Support with modifications). Note: If you chose Do not support, include the reason in the text box. If you chose Support with modifications, enter the suggested modifications in the text box. 8. Enter comments in the Comments box. Note: Comments may not be more than 2,500 characters. We suggest you develop comments in Word to check your character limit and save a copy for reference. Use the “cut and paste” function to copy your comment into the Comments box. 9. Click Submit after each comment. After you have submitted all comments, click Close. You will be able to view and download all your submitted comments. All comments are due Thursday, March 11, by 11:59 PM ET. NCQA Review of Public Comments NCQA appreciates the time and effort required to submit comments, and reviews all feedback submitted within the public comment period. Due to the high volume of comments received, NCQA cannot respond to individual comments, but NCQA advisory panels and the Committee on Performance Measurement will consider comments and advise NCQA staff. Items for Public Comment Refer to the NCQA Public Comment page for detailed documentation (memos, specifications, performance data) on the items listed below. Future of HEDIS • Introduction of Race and Ethnicity Stratification Into Select HEDIS Measures. • Roadmap for Electronic Clinical Data Systems Reporting Method. Proposed New Measures • Advance Care Planning. • Deprescribing of Benzodiazepines in Older Adults. • Antibiotic Utilization for Acute Respiratory Conditions. Proposed Changes to Existing Measures • Acute Hospital Utilization. • Use of Imaging Studies for Low Back Pain. • Mental Health Utilization. • Identification of Alcohol and Other Drug Services. • Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment. • Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence. • Comprehensive Diabetes Care. Proposed Measure Retirement • Comprehensive Diabetes Care—HbA1c Testing. • Antibiotic Utilization. Questions? Contact NCQA Customer Support at 888-275-7585, Monday–Friday, 8:30 a.m.–5:00 p.m. (ET). Proposed Changes to Existing Measures for HEDIS®1 MY 2022: Introduction of Race and Ethnicity Stratification Into Select HEDIS Measures NCQA seeks comments on the proposed addition of race and ethnicity stratifications to select HEDIS measures beginning in measurement year (MY) 2022. NCQA’s goal is to advance health equity by leveraging HEDIS to hold health plans accountable for disparities in care among their patient populations. This includes bringing transparency to where gaps exist (or do not exist) and highlighting plans that successfully invest in strategies to reduce disparities in care and outcomes. Based on feedback from expert panels, the NCQA team developed a 3-year phased approach for implementing the stratifications, with a stated goal of requiring all plans to report measure performance by race and ethnicity using directly collected2 member data by MY 2024. In MY 2022 and MY 2023, plans that meet a direct data completeness threshold of 80% for race and 80% for ethnicity will be allowed to report the stratification using their own directly collected member data for race and ethnicity. Direct data is the gold standard. Note: NCQA’s proposal is to implement indirect data for population level analysis; we recognize that indirect data is likely to be inappropriate for patient-level intervention. It is our opinion that indirect data provides a path toward transparency on disparities in quality of care in the near term. Plans that do not meet the data completeness threshold will be required to report the stratification using an approved method of indirect race and ethnicity assignment. NCQA is currently evaluating two potential approaches to specifying this stratification (Attachment). The approaches are consistent in the approved methods of direct and indirect data collection, but differ in the level at which the direct data completeness threshold must be met: • Option 1: Require data completeness at the measure level. In this approach, plans must meet the data completeness threshold for the eligible population of each measure to which this stratification applies in order to report using direct data for each measure. • Option 2: Require data completeness at the plan level. In this approach, plans must meet the data completeness threshold across their enrollment in order to report using direct data for all measures to which this stratification applies. NCQA proposes that race and ethnicity stratifications are reported separately. NCQA also proposes to define race and ethnicity categories according to existing HEDIS descriptive measure Race/Ethnicity Diversity of Membership (RDM), which aligns with Office of Management and Budget categories (Attachment). NCQA seeks general feedback on the proposal above and on the following: 1. Measures listed as candidates for stratification in MY 2022 (Attachment). In selecting these measures, NCQA evaluated them on a set of criteria, including the extent of known disparities by race and ethnicity in a particular health issue, areas that have been prioritized in state equity efforts, and whether a measure could be expected to yield small denominators if stratified. NCQA also sought to cover a wide range of health topics and include measures reported by all product lines (Medicare, Medicaid, commercial). 1 HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). 2 In developing our recommended approach, NCQA considered multiple options for implementing this stratification in HEDIS, taking into account the importance of moving toward direct data, as well as limitations of the current data environment and feasibility for implementation. In alignment with the current RDM measure, NCQA defines direct data collection as data collected directly from members (e.g., surveys, health risk assessments, disease management registries, CMS/state databases) or from enrollment information furnished by state Medicaid agencies. Indirect methods involve imputing race/ethnicity through methods such as surname analysis and geo-coding. 2. The timeline for introducing the race and ethnicity stratification to measures. A target of 5 measures will be stratified in MY 2022, with a minimum of 15 measures stratified by MY 2024. NCQA will convene a Health Equity Expert Work Group throughout 2021 to gather ongoing feedback as we review public comment responses and finalize the stratification specification. 3. Thoughts on additional measures that should be prioritized for future stratification. 4. Concerns regarding feasibility for direct/indirect methods. NCQA welcomes feedback on the details and implications of these methods. Supporting documents include the draft stratification options, the list of candidate measures and evidence workup. NCQA acknowledges the contributions of the Health Equity Expert Work Group and the internal Measures Policy team for their input and work on these proposed race/ethnicity stratifications. Race/Ethnicity Stratification Options for MY 2022 Description
Load more

Recommended publications
  • Preventing Overdiagnosis Conference Abstracts Dartmouth College September 10-12, 2013 Abstracts Are Hyperlinked
    Preventing Overdiagnosis Conference Abstracts Dartmouth College September 10-12, 2013 Abstracts are hyperlinked. Select abstract, click on it to go to chosen abstract Table of Contents Abstract#1 - THE MARMOT REPORT AND THE HAZARDS OF THE OVER-DIAGNOSIS OF BREAST CANCER .............................................................................................................................. 2 Abstract # 3 - DO PHYSICIAN SEARCHES FOR CLINICAL INFORMATION HELP TO AVOID UNNECESSARY DIAGNOSTIC TESTS, TREATMENTS OR SPECIALIST REFERRALS? ................ 3 Abstract #4 - REDUCING OVERDIAGNOSIS BY ELICITING PATIENTS’ PREFERENCES ABOUT ACCEPTABLE REGRET OF DIAGNOSTIC TESTING ......................................................................... 4 Abstract # 5 - DRIVERS FOR DIAGNOSIS OF MENTAL ILLNESS - AN ETHICAL ANALYSIS ....... 4 Abstract #6 - OVERDIAGNOSIS OF GONORRHOEA IN TREATMENT GUIDELINES FOR PELVIC INFLAMMATORY DISEASE (PID) – A RECIPE FOR RESISTANCE? ................................................. 6 Abstract # 7 - PSA-TESTING AND PROSTATIC CANCER IN DIFFERENT COUNTIES IN NORWAY – VARIATION AND OVERDIAGNOSIS ................................................................................................ 7 Abstract #8 - OVERCOMING OVERTREATMENT IN THYROID CANCER ....................................... 8 Abstract #10 - AN APPROACH TO CURB THE OVER-ORDERING OF AST, A DIAGNOSTICALLY NONSPECIFIC ENZYME ...................................................................................................................... 9 Abstract #
    [Show full text]
  • Accounting for Variation in and Overuse of Antibiotics Among Humans
    Received: 27 June 2020 Revised: 4 October 2020 Accepted: 6 October 2020 DOI: 10.1002/bies.202000163 PROBLEMS & PARADIGMS Prospects & Overviews Accounting for variation in and overuse of antibiotics among humans Martin J. Blaser1 Melissa K. Melby2 Margaret Lock3 Mark Nichter4 1 Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, New Jersey, USA 2 Department of Anthropology, University of Delaware, Newark, Delaware, USA 3 Department of Social Studies of Medicine and Department of Anthropology, McGill University, Montreal, Quebec, Canada 4 School of Anthropology, Mel and Enid Zuckerman College of Public Health, Department of Family Medicine, University of Arizona, Tucson, Arizona, USA Correspondence Martin J. Blaser, Center for Advanced Abstract Biotechnology and Medicine, Rutgers University, Piscataway NJ 08854, USA. Worldwide, antibiotic use is increasing, but many infections against which antibi- Email: [email protected] otics are applied are not even caused by bacteria. Over-the-counter and internet sales Mark Nichter, School of Anthropology, Mel and Enid Zuckerman College of Public Health, preclude physician oversight. Regional differences, between and within countries high- Department of Family Medicine, University of light many potential factors influencing antibiotic use. Taking a systems perspective Arizona, Tucson AZ 85721 Email: [email protected] that considers pharmaceutical commodity chains, we examine antibiotic overuse from the vantage point of both sides of the therapeutic relationship. We examine patterns Funding information and expectations of practitioners and patients, institutional policies and pressures, the Fondation Leducq; Canadian Institute for Advanced Research; C & D Funds; National business strategies of pharmaceutical companies and distributors, and cultural drivers Institutes of Health, Grant/Award Number: of variation.
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • Evaluation of Antibiotic Awareness Campaigns
    WHO Collaborating Centre on Patient Safety The University of Geneva Hospitals and Faculty of Medicine 4, Rue Gabrielle Perret-Gentil 1211 Geneva, Switzerland Evaluation of antibiotic awareness campaigns Report prepared by Mirko Saam, Benedikt Huttner and Stephan Harbarth1 for World Health Organization Expert Committee on the Selection and Use of Essential Medicines Policy, Access and Use (PAU) Department of Essential Medicines and Health Products 20, Avenue Appia 1211 Geneva 27, Switzerland 1 [email protected]; [email protected]; [email protected] 1 SUMMARY 1 INTRODUCTION 2 KEY FINDINGS OF THE SURVEY 3 OUTLINE OF SURVEYED CAMPAIGNS 3 TARGET AUDIENCES 5 INFECTIONS TARGETED 7 KEY MESSAGES AND ESSENTIAL PUBLIC SLOGANS 8 GLOBAL VERSUS LOCAL KEY MESSAGES 11 “NEW” KEY MESSAGES IDENTIFIED 12 INTERVENTIONS USED IN THE CAMPAIGNS 13 EVALUATION OF THE CAMPAIGNS 14 OBSTACLES FACED WHILE IMPLEMENTING A PUBLIC AWARENESS CAMPAIGN 15 POTENTIAL FOR EXPANSION IN NEW DIRECTIONS 15 ACKNOWLEDGMENTS 17 APPENDIX I - METHODOLOGY I APPENDIX II - SUMMARY TABLE I APPENDIX III - QUESTIONNAIRE USED FOR THE SURVEY I REFERENCES 18 2 SUMMARY ● Between September and November 2016, we conducted an online survey to review the characteristics of public awareness campaigns targeting antibiotic use conducted since 2010. We identified 60 campaigns implemented on a national (n=42, 70%), regional (14, 23%) or both levels simultaneously (2, 2%), across 16 low- and middle- income countries (LMICs), and 31 high-income countries. Respondents from another 8 countries (5 LMICs and 3 high-income countries) either stated they were not sure, or that there was no such campaign in their country. Among the 93 countries that were contacted, 38 (40%) did not respond at all.
    [Show full text]
  • Trends in Antibiotic Self-Medication for Dental Pathologies Among Patients in the Dominican Republic: a Cross-Sectional Study
    Journal of Clinical Medicine Article Trends in Antibiotic Self-Medication for Dental Pathologies among Patients in the Dominican Republic: A Cross-Sectional Study Juan Manuel Aragoneses 1, Javier Aragoneses 2 , Cinthia Rodríguez 3, Juan Algar 4 and Ana Suárez 5,* 1 Faculty of Dentistry, Universidad Alfonso X El Sabio, 28691 Madrid, Spain; [email protected] 2 Department of Medicine and Medical Specialties, Faculty of Health Sciences, University of Alcalá, 28801 Madrid, Spain; [email protected] 3 Department of Dentistry, Universidad Federico Henriquez y Carvajal, Santo Domingo 10106, Dominican Republic; [email protected] 4 Department of Clinical Dentistry, School of Biomedical Sciences, Universidad Europea de Madrid, 28005 Madrid, Spain; [email protected] 5 Department of Preclinical Dentistry, School of Biomedical Sciences, Universidad Europea de Madrid, 28670 Madrid, Spain * Correspondence: [email protected] Abstract: The World Health Organisation has warned of the increase in antibiotic resistance, esti- mating that by 2050 it could become the leading cause of death worldwide. Several studies and literature reviews show a correlation between antibiotic use and bacterial resistance, with unnecessary broad-spectrum antibiotics, such as amoxicillin/clavulanic acid and azithromycin, being one of the main causative factors. An interview-based survey of 2160 participants was conducted to assess the Citation: Aragoneses, J.M.; prevalence in the practice of self-medication with antibiotics among dental patients in the Dominican Aragoneses, J.; Rodríguez, C.; Algar, Republic. A series of open-ended questions regarding self-medication and class of antibiotics were J.; Suárez, A. Trends in Antibiotic put to the patients. Over a third of the study population (39.7%) admitted to the practice of antibiotic Self-Medication for Dental Pathologies among Patients in the self-medication.
    [Show full text]
  • Situation Report on the Active Substance Amoxicillin
    INSPECTION DIVISION Starting materials inspection division Date: 30/03/2016 Version: 1 public Status: Final SITUATION REPORT ON THE ACTIVE SUBSTANCE AMOXICILLIN I. INTRODUCTION .................................................................................................................................. 2 II. BACKGROUND .................................................................................................................................. 3 III. APPLICABLE REGULATIONS/GUIDELINES IN FORCE ................................................................ 3 IV. AMOXICILLIN SUPPLY .................................................................................................................... 3 IV.1. Process for obtaining amoxicillin ................................................................................................ 3 IV.2. Sources of supply of medicinal product manufacturing sites in France ..................................... 5 V. EVALUATION OF AMOXICILLIN MANUFACTURERS BY PHARMACEUTICAL SITE .................. 8 VI. REVIEW OF RECENT INSPECTIONS .............................................................................................. 8 VI.1. Collaboration between competent authorities ............................................................................ 8 VI.2. Monitoring of amoxicillin (sodium or trihydrate) manufacturing sites by international authorities since 2010 ..........................................................................................................................................
    [Show full text]
  • Employment and Activity Limitations Among Adults with Chronic Obstructive Pulmonary Disease — United States, 2013
    Morbidity and Mortality Weekly Report Weekly / Vol. 64 / No. 11 March 27, 2015 Employment and Activity Limitations Among Adults with Chronic Obstructive Pulmonary Disease — United States, 2013 Anne G. Wheaton, PhD1, Timothy J. Cunningham, PhD1, Earl S. Ford, MD1, Janet B. Croft, PhD1 (Author affiliations at end of text) Chronic obstructive pulmonary disease (COPD) is a group a random-digit–dialed telephone survey (landline and cell of progressive respiratory conditions, including emphysema phone) of noninstitutionalized civilian adults aged ≥18 years and chronic bronchitis, characterized by airflow obstruction that includes various questions about respondents’ health and and symptoms such as shortness of breath, chronic cough, risk behaviors. Response rates for BRFSS are calculated using and sputum production. COPD is an important contributor standards set by the American Association of Public Opinion to mortality and disability in the United States (1,2). Healthy Research Response Rate Formula #4.† The response rate is the People 2020 has several COPD-related objectives,* including number of respondents who completed the survey as a pro- to reduce activity limitations among adults with COPD. To portion of all eligible and likely eligible persons. The median assess the state-level prevalence of COPD and the associa- survey response rate for all states, territories, and DC in 2013 tion of COPD with various activity limitations among U.S. was 46.4%, and ranged from 29.0% to 60.3%. Additional adults, CDC analyzed data from the 2013 Behavioral Risk information is presented in the BRFSS 2013 Summary Data Factor Surveillance System (BRFSS). Among U.S. adults in Quality Report.§ all 50 states, the District of Columbia (DC), and two U.S.
    [Show full text]
  • The Selection and Use of Essential Medicines
    WHO Technical Report Series 1006 The Selection and Use of Essential Medicines Report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children) WHO Technical Report Series 1006 The Selection and Use of Essential Medicines Report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th WHO Model List of Essential Medicines for Children) This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO model list of essential medicines and the 6th WHO model list of essential medicines for children). (WHO technical report series ; no. 1006) ISBN 978-92-4-121015-7 ISSN 0512-3054 © World Health Organization 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence.
    [Show full text]
  • Together, Let's Save Antibiotics
    TOGETHER, LET’S SAVE ANTIBIOTICS Proposals of the special working group for keeping antibiotics effective Together, let’s save antibiotics Written by : Dr Jean CARLET and Pierre LE COZ 2 TOGETHER, LET’S SAVE ANTIBIOTICS REPORT FROM THE SPECIAL WORKING GROUP FOR KEEPING ANTIBIOTICS EFFECTIVE June 2015 TOGETHER, LET’S SAVE ANTIBIOTICS 3 Acknowledgements My sincere thanks go first and foremost to Marisol Touraine, the French Minister of Social Affairs, Health and Women’s Rights, for entrusting me with this assignment. I would also like to thank the cabinet ministers, especially Professor Djillali Annane and Dr Jérôme Salomon for their well-informed advice. I am grateful to Professor Benoît Vallet, Director-General for Health, for his encouragements throughout this assignment, and to Dr Marie-Hélène Loulergue, Deputy-Director of Infection Risk Prevention, her assistant Dr Bernadette Worms and their team for their warm welcome. I would like to highlight the involvement and commitment of the working group coordinators, Dr Bruno Coignard, Deputy Director of the Department of Infectious Diseases at the French Institute for Public Health Surveillance (InVS), Professor Céline Pulcini, infectious diseases consultant at Nancy Teaching Hospital (CHU), Ms Claude Rambaud, Vice-President of the Collectif Inter-associatif Sur la Santé (CISS), Mr Alain-Michel Ceretti, Founder and Chairman of LIEN, Professor Jocelyne Arquembourg, lecturer at the University of Paris III – Sorbonne Nouvelle, Ms Florence Séjourné, Managing Director of the biotech Da Volterra,
    [Show full text]
  • Call for More Research to Contain Antimicrobial Resistance Waleed M
    Sweileh Globalization and Health (2021) 17:94 https://doi.org/10.1186/s12992-021-00754-9 RESEARCH Open Access Global research publications on irrational use of antimicrobials: call for more research to contain antimicrobial resistance Waleed M. Sweileh Abstract Background: Irrational use of antimicrobials is highly prevalent. It is a major driving factor for antimicrobial resistance (AMR). Research on irrational antimicrobial use is important for developing policies and regulations to combat and contain AMR. The present study aims to provide an overview of research publications on the irrational use of antimicrobials at the national and global levels. Methods: Publications on irrational use of antimicrobials were extracted from Scopus using a wide range of relevant keywords for the study period from 1980 to 2020. Results: In total, 656 publications on irrational use of antimicrobials were found. The bulk of publications in this field were about irrational use in humans. A limited number of publications were found on the irrational use of antimicrobials in the context of veterinary and environment. The number of publications, contributing countries, and the mean number of authors per article increased with time, most notably in the last decade. Authors from 105 different countries participated in publishing the retrieved articles with 22 (21.0%) participated in 10 or more publications. The United States led with 140 (21.6%) articles followed distantly by China (n = 49, 7.5%), India (n = 45, 6.9%), and the United Kingdom (n = 45, 6.9%). Countries in the South-East Asian region (n = 69, 10.5%) and the African region (n = 42, 6.4%) made the least contribution.
    [Show full text]
  • Towards a New Global Business Model for Antibiotics
    Towards a New Global Business Model for Antibiotics Global Business Model for a New Towards Chatham House Report Edited by Charles Clift, Unni Gopinathan, Chantal Morel, Kevin Outterson, John-Arne Røttingen and Anthony So Towards a New Global Business Model for Antibiotics Edited by Charles Clift, Gopinathan, and Anthony John-ArneSo Outterson, Charles Chantal Unni Kevin Røttingen by Morel, Edited Delinking Revenues from Sales Report from the Chatham House Working Group on New Antibiotic Business Models Chatham House Chatham House Report Edited by Charles Clift, Unni Gopinathan, Chantal Morel, Kevin Outterson, John-Arne Røttingen and Anthony So October 2015 Towards a New Global Business Model for Antibiotics Delinking Revenues from Sales Report from the Chatham House Working Group on New Antibiotic Business Models Chatham House, the Royal Institute of International Affairs, is an independent policy institute based in London. Our mission is to help build a sustainably secure, prosperous and just world. The Royal Institute of International Affairs Chatham House 10 St James’s Square London SW1Y 4LE T: +44 (0) 20 7957 5700 F: + 44 (0) 20 7957 5710 www.chathamhouse.org Charity Registration No. 208223 © The Royal Institute of International Affairs, 2015 Chatham House, the Royal Institute of International Affairs, does not express opinions of its own. The opinions expressed in this publication are the responsibility of the authors. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical including photocopying, recording or any information storage or retrieval system, without the prior written permission of the copyright holder.
    [Show full text]
  • Antibiotic Stewardship
    CME Infectious diseases Clinical Medicine 2013, Vol 13, No 5: 499–503 28 Department of Health Advisory Committee encompass initiatives that promote the on Antimicrobial Resistance and Healthcare Antibiotic responsible use of antibiotics, with the goal of Associated Infection. Antimicrobial steward- preserving their future effectiveness and safe- ship: ‘Start smart – then focus’. London: DH, stewardship 4–7 2011. www.gov.uk/government/uploads/ guarding public health. The physician may system/uploads/attachment_data/file/215308/ perceive the concept of stewardship as pat- dh_131181.pdf [Accessed 5 August 2013]. Kieran Hand, consultant pharmacist for ronising or insulting and a threat to clinical anti-infectives and post-doctoral clinical freedom; nonetheless, physicians in the USA academic fellow have recently called for mandatory imple- Address for correspondence: mentation of antibiotic stewardship backed Dr RA Seaton, Brownlee Centre for University Hospital Southampton NHS Foundation Trust by legislation.8 This article sets out the case Infectious Diseases, Gartnavel General for antibiotic stewardship and describes com- Hospital, 1053 Great Western Road, monly used stewardship strategies and the Glasgow G12 0YN. Introduction evidence supporting their effectiveness. Email: [email protected] Sir Frank MacFarlane Burnet, winner of the Nobel Prize for Medicine in 1960, wrote of the Misuse of antibiotics decline of infectious diseases in 1962: ‘One can Antibiotic misuse (Table 1) is common in the think of the middle of the twentieth
    [Show full text]